Pall T. Onundarson: This JACC Review is Highly Biased in Favor of DOAC Drugs
Pall T. Onundarson, Professor Emeritus at Landspitali University Hospital, shared a post on LinkedIn:
“Bruno, is careful in how he chooses his words but this JACC review is highly biased in favor of DOAC drugs, just look at the whole page list of disclosures. All the studies quoted compare DOAC drugs to conventional old PT-INR monitoring of warfarin that we know today is a suboptimal monitoring method that leads to suboptimal outcomes with warfarin.
Why does the paper not mention that there are major improvements in warfarin and VKA treatment and monitoring (self-monitoring and dosing, Fiix monitoring) that could benefit patients and payers massively? To whose benefit is it to silence that such improvements exist and deserve better study? What do patients and regulators think of not being made aware of such potential benefit by medical doctors? Why are reagent and instrument manufacturers afraid of investing in such improvements if patients and payers could benefit?”
Quoting Bruno Pougault’s post:
“DOACs may not be as efficacious or as safe as the current standard of care in conditions such as mechanical heart valves, thrombotic antiphospholipid syndrome, and atrial fibrillation associated with rheumatic heart disease”
Title: When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review
Authors: Antoine Bejjani, Candrika D Khairani, Ali Assi, Gregory Piazza, Parham Sadeghipour, Azita H Talasaz, John Fanikos, Jean M Connors, Deborah M Siegal, Geoffrey D Barnes, Karlyn A Martin, Dominick J Angiolillo, Dawn Kleindorfer, Manuel Monreal, David Jimenez, Saskia Middeldorp, Mitchell S V Elkind, Christian T Ruff, Samuel Z Goldhaber, Harlan M Krumholz, Roxana Mehran, Mary Cushman, John W Eikelboom, Gregory Y H Lip, Jeffrey I Weitz, Renato D Lopes, Behnood Bikdeli
Read full paper here.
Stay informed with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia